0QUT.LSE Episurf Medical AB Series B
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2022.
Is 0QUT.LSE undervalued?
Graham numberThe Graham number of Episurf Medical AB Series B cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Episurf Medical AB Series B fundamental analysis
No fundamental analysis for Episurf Medical AB Series B yet.
Episurf Medical AB Series B stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Episurf Medical AB Series B
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat o…
Full company profileEpisurf Medical AB Series B financial statements
2022 annualized: Fiscal year 2022 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2022, the balance sheet is the latest quarter. Figures change when the annual report is published.
Episurf Medical AB Series B annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 2.66M | 3.09M | 4.30M | 5.40M | 7.00M | - | - |
| Operating Income | -61.7M | -61.2M | -57.5M | -68.9M | -63.4M | - | - |
| Net Income | -61.7M | -61.1M | -57.8M | -69.8M | -63.9M | - | - |
| Balance Sheet | |||||||
| Total Assets | - | - | 54.8M | 57.6M | 185M | - | - |
| Total Liabilities | - | - | 10.0M | 16.2M | 15.9M | - | - |
| Shareholders' Equity | - | - | 44.8M | 41.4M | 170M | - | - |
| Cash & Short-term Investments | - | - | 28.3M | 25.3M | 155M | - | - |
| Total Debt | - | - | - | 3.50M | 1.50M | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -56.1M | -61.4M | -52.3M | -59.2M | -54.1M | -59.7M | - |
| Capital Expenditure | 5.56M | 32.7K | 100K | 100K | 100K | 100K | - |
| Ratios | |||||||
| ROE | - | - | -129.0% | -168.6% | -37.7% | - | - |
| ROA | - | - | -105.5% | -121.2% | -34.5% | - | - |
| Net Profit Margin | -2,317.9% | -1,975.0% | -1,344.2% | -1,292.6% | -912.9% | - | - |
| Debt to Equity | - | - | - | 0.08x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Episurf Medical AB Series B dividends
Episurf Medical AB Series B has not paid dividends in the last 9 fiscal years.
Last stock split: 160:109 on Aug 5, 2025.
Who owns Episurf Medical AB Series B
- Insiders 51.98%
- Institutions 15.09%
- Public & others 32.94%
- Free float 3.39B
Episurf Medical AB Series B company profile
- Company name
- Episurf Medical AB Series B
- Ticker
- 0QUT.LSE
- ISIN
- SE0003491562
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 22
- Fiscal year end
- December
- Address
- KarlavAegen 60, Stockholm, Sweden, 114 49
- Phone
- 46 86 12 00 20
- Website
- episurf.com
About Episurf Medical AB Series B
Episurf Medical AB (publ), a medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally. It provides Episealer Knee for repairing focal cartilage and bone defects to reduce pain and increase mobility in the patient's knee joint; Episealer implant, which is designed to fit anatomy and size of the lesion; Episealer toolkit; and Episealer Patellofemoral System, a system to treat osteoarthritis limited to the patellofemoral part of the knee joint. The company also offers Epioscopy to identify and visualize femoral knee joint cartilage and bone lesions, and tibia, as well as defects on the cruciate ligaments and menisci; Epiguide, a surgical drill guide; and µiFidelity, a web platform for order management, communication, personalized design, and surgical pre-planning. In addition, it is developing Episealer MTP implant, an implant for the MTP joint of the big toe in the foot. Further, the company offers Talus Osteotomy Guide (TOG) that is designed to fit on the patient's distal tibia using CT and MRI images; MRI protocol to ensure correct damage assessment, 3D visualization, and device design; and Damage Marking Report (DMR) that enables 3D visualization of damage in the joint surface and underlaying bone defects, as well as other findings relevant when selecting the right treatment for the patient. It also holds logistics and warehouse properties in Helsinki and Kerava. The company was formerly known as Diamorph Medtech AB and changed its name to Episurf Medical AB (publ) in 2010. Episurf Medical AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
Episurf Medical AB Series B management
9- Dr. Leif RydConsultant, Member of Clinical Advisory Board & Director · born 1949
- Ms. Katarina Flodström Ph.D.Deputy CEO & Head of Medical Technology Operations · born 1975
- Mr. Jens AnderssonCEO & Director · born 1973
- Ms. Sanja BatljanChief Financial Officer · born 1967
- Mr. Fredrik ZetterbergMarketing Director · born 1975
- Ms. Ylva BondeHead of Quality & Regulatory Affairs · born 1979
- Ms. Petra Widen LindhHead of Property Management
- Mr. Christian OlofssonDeputy CEO & Head of Business Development
- Mr. Patrick JamnikPresident of Episurf Medical Inc · born 1983